The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 31, 2023
Filed:
Aug. 26, 2019
Applicant:
Oncosec Medical Incorporated, Pennington, NJ (US);
Inventors:
Robert H. Pierce, Seattle, WA (US);
Adil Daud, Hillsborough, CA (US);
Assignee:
OncoSec Medical Incorporated, San Diego, CA (US);
Primary Examiner:
Int. Cl.
CPC ...
A61K 48/00 (2006.01); C07K 16/28 (2006.01); A61N 1/32 (2006.01); A61K 38/19 (2006.01); A61K 39/395 (2006.01); A61K 38/20 (2006.01); C07K 14/54 (2006.01); A61N 1/36 (2006.01);
U.S. Cl.
CPC ...
A61K 48/0091 (2013.01); A61K 38/19 (2013.01); A61K 38/208 (2013.01); A61K 39/3955 (2013.01); A61N 1/327 (2013.01); C07K 14/5434 (2013.01); C07K 16/2818 (2013.01); A61N 1/36002 (2017.08); C07K 2317/569 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01); C12N 2800/22 (2013.01);
Abstract
The present invention provides for the intratumoral delivery of at least one immunostimulatory cytokine in combination with at least one checkpoint inhibitor. In particular, it provides delivery of a plasmid encoding the immunostimulatory cytokine using intratumoral electroporation. The checkpoint inhibitor may be administered systemically or encoded on a plasmid and delivered using intratumoral electroporation. The checkpoint inhibitor may be delivered contemporaneously with or after treatment with the immunomodulatory cytokine.